Current Landscape and Emerging Therapeutic Targets in Diabetic Kidney Disease - PubMed
3 days ago
- #CKM Syndrome
- #Diabetic Kidney Disease
- #Therapeutic Targets
- Diabetic kidney disease (DKD) is a major global health burden and the leading cause of end-stage kidney disease.
- Therapeutic strategies have evolved from a glucocentric approach to a multifaceted management of cardiovascular-kidney-metabolic syndrome (CKM).
- Four foundational pillars of DKD treatment include RAASi, SGLT2i, GLP-1RAs, and ns-MRAs, targeting complementary pathogenic pathways.
- Despite advancements, residual risk remains high, prompting research into novel therapeutic targets.
- Emerging therapies focus on histone-modifying enzymes, metabolic/lipid disorder correction, anti-inflammatory/anti-fibrosis drugs, and stem cell-based interventions.
- Future challenges include clinical trial design, patient stratification using biomarkers, and synergistic combination therapies for personalized treatment.